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Aberrant glycosylation is a hallmark of cancer cells with increased evidence pointing
to a role in tumor progression. In particular, aberrant sialylation of glycoproteins and
glycolipids has been linked to increased immune cell evasion, drug evasion, drug
resistance, tumor invasiveness, and vascular dissemination, leading to metastases.
Hypersialylation of cancer cells is largely the result of overexpression of sialyltransferases 
(STs). Differentially, humans express twenty different STs in a tissue-specific manner, each 
of which catalyzes the attachment of sialic acids via different glycosidic linkages (α2-3,
α2-6, or α2-8) to the underlying glycan chain. One important mechanism whereby over-
expression of STs contributes to an enhanced metastatic phenotype is via the generation 
of selectin ligands. Selectin ligand function requires the expression of sialyl-Lewis X and
its structural isomer sialyl-Lewis A, which are synthesized by the combined action of
alpha α1-3-fucosyltransferases, α2-3-sialyltransferases, β1-4-galactosyltranferases, and 
N-acetyl-β-glucosaminyltransferases. The α2-3-sialyltransferases ST3Gal4 and ST3Gal6 
are critical to the generation of functional E- and P-selectin ligands and overexpression
of these STs have been linked to increased risk of metastatic disease in solid tumors and 
poor outcome in multiple myeloma. Thus, targeting selectins and their ligands as well as
the enzymes involved in their generation, in particular STs, could be beneficial to many
cancer patients. Potential strategies include ST inhibition and the use of selectin antag-
onists, such as glycomimetic drugs and antibodies. Here, we review ongoing efforts to
optimize the potency and selectivity of ST inhibitors, including the potential for targeted
delivery approaches, as well as evaluate the potential utility of selectin inhibitors, which
are now in early clinical development.
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iNTRODUCTiON
It is well established that one of the most frequent changes in cancer cells is the pattern of cell surface 
glycosylation (1, 2). Because glycans present on the plasma membrane influence the ability of cells 
to interact with their surrounding microenvironment, altered glycosylation enables cancer cells to 
acquire specific capabilities to interact with all components of the microenvironment, such as growth 
factors, chemokines, extracellular matrix, and cell to cell contact. As a consequence, processes such 
as adhesion, mobilization, and migration are also altered in cancer (3). The glycosylation pattern 
of cancer cells may also change during disease progression; indeed, metastatic cancer cells display 
profound differences in cell surface glycosylation, compared not only to the normal cells but also to 
FiGURe 1 | (A) Structure of N-acetylneuraminic acid. (B) Structure of 
cytidine-5′-monophospho-(CMP)-sialic acid. (C) Types of sialic acid linkages 
catalyzed by the different members of the mammalian ST family.
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the original tumor (4–7). Changes in glycans on cancer cells often 
arise from a combination of mechanisms, such as overexpres-
sion or downregulation of the glycan’s protein or lipid scaffold 
or modifications of the metabolic pathways responsible for the 
generation of specific glycans (1).
One of such changes in the glycome of cancer cells is the 
increased presence of sialic acid sugars on the surface of 
cancerous cells (8). Hypersialylation of tumor cells has been 
associated with a metastatic phenotype and inferior outcome in 
patients with cancer (9). Sialic acids represent a group of sugars 
based on the neuraminic acid scaffold, with the most frequent 
being N-acetylneuraminic acid (Neu5Ac; Figure  1A). Sialic 
acids are predominantly found at the non-reducing termini of 
N- and O-linked glycans attached to proteins or on glycolipids. 
Sialylation of glycans is carried out by a complex, yet highly 
specific, series of enzymatic processes that take place in the ER–
Golgi apparatus, and are responsible for the covalent linkage of 
sialic acids to galactose (Gal), N-acetylgalactosamine (GalNAc), 
N-acetylglucosamine (GlcNAc), or to another sialic acid (poly-
sialic acids). These enzymatic reactions are performed by a class 
of glycosyltranferases termed the sialyltransferases (STs).
THe SiALYLTRANSFeRASe FAMiLY
The ST family is part of the larger glycosyltransferase superfamily 
generally expressed in the secretory pathway. Recently, there has 
been a surge in structural understanding of the family, knowledge 
of which members is involved in biosynthesis of selectin ligands 
under both healthy and cancerous conditions, and advances in 
the ability to inhibit STs with a cell permeable inhibitor.
Overview of the ST Family
In humans, the ST family is composed of 20 individual members 
(10–12). These enzymes are expressed in a cell- and tissue-
specific manner, proving each cell type with a unique “sialome” 
(13). All mammalian STs use cytidine-5′-monophospho-(CMP)-
sialic acid (Figure 1B) as their donor substrate and a glycan as 
their receptor. Exquisite stereoselectivity results in ST-catalyzed 
formation of an α-linked sialic acid to a precise hydroxyl group 
on a specific particular saccharide residue. The combination of 
the acceptor saccharide residue and the precise hydroxyl group 
on this residue can be used to divide the family into four distinct 
families (Figure 1C) (11, 12, 14). For example, ST6Gal enzymes 
catalyze the transfer of sialic acid to the 6′-hydroxyl group of a 
Gal residue, ST3Gal enzymes catalyze the transfer of sialic acid 
to the 3′-hydroxyl group of a Gal residue, ST3GalNAc enzymes 
catalyze the transfer of sialic acid to the 6′-hydroxyl group of a 
GalNAc, and ST3Sia enzymes catalyze the transfer of sialic acid 
to the 8′-hydroxyl group of another sialic acid residue.
All mammalian STs belong to glycosyltransferase family 29 
(GT29) in the CAZy database (www.cazy.org). Only recently, the 
first structures of mammalian STs have been solved. The first was 
ST3Gal1 from porcine (15), which is the enzyme that masks the 
peanut agglutinin (PNA) ligand (Galβ1-3GalNAc) on complex 
O-glycans. The structure of ST3Gal1 showed for the first time 
how active site residues position the appropriate hydroxyl group 
on the acceptor for nucleophilic attack. Structures of both rat and 
human ST6Gal1 were also recently solved (16, 17). Fortuitously, 
the complex N-glycan on a neighboring dimeric unit was trapped 
in the active site of the human enzyme, providing structural 
insight into the well described preference of this enzyme for the 
α1-3 mannose branch on complex N-glycans. Further structural 
insight into this sub-family of ST awaits a cocrystal structure in 
which electron density of sialic acid is clearly observed. More 
recently, the structure of ST8Sia3 was determined, which has 
led to insight into how this sub-family uses a positively charged 
groove to position the extended polysialic acid oligosaccharide 
acceptor (18). Together, the structures of the first three mam-
malian STs provide an excellent starting point for understanding 
the structure basis for catalysis by the mammalian ST family. 
Nevertheless, there is much more work to be done in determining 
how different the active site architecture is between the different 
STs; based on differences observed in the three structures solved 
to date, it seems reasonable to speculate that, although challenge, 
it may be possible to exploit differences between members of 
the family to ultimately develop selective inhibitors that target 
individual sub-classes, or even members, of the ST family.
Sialyltransferase Overexpression in 
Cancer
Many of the STs are overexpressed in various forms of cancer, 
which has been reviewed in detail elsewhere (19–24). In many 
cases, this overexpression has been correlated with cell surface 
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overexpression of the product for that particular ST. For example, 
many cancer cells overexpress ST6Gal1, and as a consequence, 
stain strongly with the Sambucus nigra (SNA) lectin that recognizes 
sialic acid residues α2-6-linked to Gal (22). In another example, 
gliomas were shown to express ST3Gal1, which correlated with 
low staining of cells and tumors by PNA (25). On the other hand, 
several reports have also documented that loss or downregulation 
of ST expression correlates with cancer progression (26, 27). These 
findings highlight the need for careful studies that systematically 
modulate ST expression and activity to determine whether it is 
simply aberrant glycosylation or specifically hypersialylation that 
plays a role in tumor progression.
Overexpression of STs and the resultant hypersialylation in 
cancer has been implicated in many stages of tumorigenesis (7, 
20, 21, 24). Studies have documented the roles for hypersialylation 
in drug and radiation resistance (28, 29). Recent work has found 
that hypersialylation is also involved in evasion from the immune 
system, with numerous types of cancer cells expressing high 
levels of sialylated ligands of the inhibitory receptors sialic acid-
binding, immunoglobulin-like lectin-(Siglec)-7 and Siglec-9, 
which in turn recruit these Siglecs to inhibit natural killer (NK) 
cell killing (30, 31) or neutrophil activation (32). Hypersialylation 
is also implicated in enhancing tumor invasiveness by enhancing 
cellular proliferation and motility through constitutive activa-
tion of pathways involved in cell growth and motility (33, 34). 
A critical role for hypersialylation in cancer metastasis has also 
been suggested for certain types of cancer. For example, sialylated 
ligands of the Selectin family of adhesion proteins ligands have 
been described on multiple myeloma (MM) cells (35, 36) and 
breast cancer cells (37) and have been shown to be critical for 
homing and metastasis of these cancer cells. Similar observations 
are suggested based on correlative studies in renal cell carcinoma 
(38) and lung cancer (39). Based on the broad therapeutic interest 
around preventing cancer metastasis, this aspect is described in 
more detail in the following section.
SeLeCTiN AND THeiR LiGANDS iN 
CANCeR MeTASTASiS
Sialic acids are incorporated within many different carbohydrate 
structures, including sialyl Lewis X (SLex) and its isomer sialyl 
Lewis A (SLea; Figure  2). These tetrasaccharide structures are 
composed of α2-3-linked sialic acid on the GlcNAc backbone. 
SLex and SLea represent the minimal recognition motif for ligands 
of selectins, a family of lectins whose functions are well character-
ized as mediators of leukocytes trafficking (40, 41). Three types 
of selectins have been described so far, the L-, E-, and P-selectins. 
Selectins are type I membrane proteins composed of a N-terminus 
C-type lectin domain followed by an epidermal growth factor 
(EGF)-like motif, a series of consensus repeats, a transmembrane 
domain, and a short cytoplasmatic tail. By interacting with SLex 
and SLea containing glycoproteins and glycolipids, selectins 
are responsible for the slow tethering and rolling of leukocytes 
on the vascular endothelium that is the first step of leukocytes 
extravasation during inflammation or lymphocytes homing. As 
is often seen during oncogenic transformation, cancer cells take 
advantage of this physiological process to spread and colonize 
to distant organs during the metastatic cascade (3, 42). Indeed, 
extravasation of tumor cells during metastasis is the best docu-
mented function of selectins and their ligands in cancer (43–45). 
However, recent evidence suggests a role of selectins/selectin 
ligands interactions beyond the extravasation process, such as 
emboli formation, formation of a permissive microenvironment 
for metastasis, and retention of tumor cells in protective niches.
Selectins and Their Ligands during 
extravasation and Homing of Cancer Cells
Selectins have been directly implicated in tumor extravasation for 
their ability to support tumor cell rolling on activated endothelium 
in a process that mirrors leukocytes extravasation. In a small cell 
lung cancer xenograft model, it has been shown that cancer cells 
rolled in vivo on tumor necrosis factor α-(TNFα-) treated vessels, 
although the rolling velocity was seven times faster than that of 
leukocytes (46). Moreover, when cancer cells were transplanted in 
E- and P-selectin knockout (KO) mice, the number of metastases 
was significantly lower than wild-type (WT) mice, demonstrat-
ing the importance of selectins in metastases. The capability 
of a particular tumor to extravasate and therefore metastasize 
might correlate with the expression levels of selectin ligands. 
In colon carcinoma, there was a direct association between the 
levels of E-selectin ligands and the metastatic phenotype (47). 
Colorectal cancer cells expressing high levels of SLea extravasate 
more efficiently than cancer cells with low SLea in vivo. Similarly, 
the highly metastatic breast cancer cell line ZR-75-1 establishes 
stronger interactions with E-selectin in  vitro compared to the 
less metastatic cell line MCF7 (48). Curiously, Mucin-1 (MUC-
1) serves as the E-selectin ligand in these cells but also enables 
firm adhesion by binding to intracellular adhesion molecule-1 
(ICAM-1) suggesting that selectin scaffolds may have more than 
one role during tumor extravasation. Mouse prostate cancer 
cells engineered to overexpress fucosyltransferase (FUT)3, 6, 
and 7, show different ability to roll on E-selectin in  vitro with 
the FUT6-overexpressing cells displaying the highest number 
of rolling cells (49). Accordantly, the FUT6-overexpressing cells 
exhibit the highest metastatic potential in the bone compared to 
FUT3 and FUT7-overexpressing cells. Recently, we have shown 
that MM cells overexpress ST3Gal6 and have high levels of α2-3-
linked sialic acid on the cell surface, suggesting a role of selectin 
ligands in homing of MM to the bone marrow (36). Knocking 
down ST3Gal6 decreased the levels of α2-3-linked sialic acid, 
impaired transendothelial migration of myeloma cell in vitro, and 
importantly reduced homing in  vivo, indicating that the levels 
of selectin ligands influences myeloma trafficking into the bone 
marrow niche.
The ability of tumor cells to interact with selectins has been 
proposed to correlate to some extent with disease progression. In 
MM, we observed that the expression levels of ST3Gal6 increased 
with disease progression (36). Moreover, the P-selectin glycopro-
tein ligand-1 (PSGL-1) gene expression was found to increase 
with disease progression and, more recently, the percentage of 
potential E-selectin ligands bearing primary myeloma cells was 
shown to be higher in relapsed versus diagnosed patients (50, 51). 
FiGURe 2 | Structure of SLex (A) and its structural isomer SLea (B).
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Similarly, in acute myeloid leukemia (AML), the expression of 
E-selectin ligands is higher in relapsed compared to newly diag-
nosed patients (52). In prostate cancer, the ex vivo interactions 
between circulating tumor cells (CTC) isolated from patients and 
E-selectin on activated endothelial cells correlated with the clini-
cal response of castration resistant prostate cancer patients with 
no interactions during clinical response and many interactions 
at time of tumor progression (53). These data suggest a dynamic 
modulation of selectin ligands expression as the disease develops 
to a more aggressive phenotype.
Expression of selectins may also dictate to some extent tissue 
tropism for metastatic cancer cells. Transgenic mice overex-
pressing E-selectin in the liver have the propensity to develop 
hepatic metastasis when injected with melanoma cells expressing 
E-selectin ligands (54). In this system, murine melanoma cells 
that naturally metastasize to the lungs were engineered to express 
E-selectin ligands and injected in WT or transgenic mice with 
ubiquitously or liver specific expression of E-selectin. Liver 
metastases were observed only in E-selectin transgenic mice. The 
prevalence of liver metastasis, even in mice where E-selectin was 
ubiquitously expressed at similar levels in all tissues, indicates 
that additional factors influence the metastatic process. The large 
vasculature in combination with low shear stress typical of the 
liver may provide tumor cells with more potential adhesive sites 
than other organs. E-selectin dependency was also demonstrated 
in  vivo for spontaneous breast metastasis to the lung and in a 
murine model of spontaneous liver metastasis (55, 56). In both 
studies, expression of E-selectin in the vasculature was dependent 
on pro-inflammatory and pro-angiogenic cytokines induced or 
even released by tumor cells, suggesting that primary tumors may 
promote an inflammatory activation of the endothelium in dis-
tant organs to facilitate metastatic seeding (56, 57). Selectins were 
also involved in engraftment of chronic myelogenous leukemia 
(CML) and chronic eosinophilic leukemia (CEL) in a severe com-
bined immunodeficiency (SCID) mouse xenograft model (58). 
E- and P-selectin KO mice that were injected with leukemic cells 
displayed remarkably increased survival and little organ infiltra-
tion compared to WT mice. Moreover, the murine breakpoint 
cluster region-Abelson 1 positive (BRC-ABL1+) progenitor cells 
that resemble human CML demonstrated low engraftment in 
recipient mice deficient for E-selectin (59). Murine BRC-ABL1+ 
progenitor cells deficient either in PSGL-1, CD44, and FUT4, 7 or 
core2 β1-6-N-acetylglucosaminyl-transferase (core2 GlcNAcT-I) 
were impaired for engraftment.
Selectins other than E-selectin are also implicated in tumor 
extravasation and homing. In the previous study, L-selectin was 
also shown to be important for BRC-ABL1+ progenitor cells hom-
ing in the bone marrow (59). Recently, L-selectin has been shown 
to be one of the key receptors for chronic lymphocytic leukemia 
(CLL) homing and extravasation into the lymph nodes, an impor-
tant niche where CLL cells proliferate and become resistant to 
chemotherapy (60). L-selectin was also shown to facilitate tumor 
metastases by recruiting leukocytes at sites of tumor emboliza-
tion (61). Leukocytes may assist extravasation by bridging tumor 
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cells or thrombi to the vascular endothelium and breaching the 
endothelial barrier. Indeed, E-selectin is frequently upregulated 
in the endothelium of the metastatic environment (62). Since 
L-selectin is an E-selectin ligand (63, 64), E-selectin present on 
the metastatic endothelium may contribute to leukocyte recruit-
ment and establishment of a metastatic niche. Recently, the 
expression of PSGL-1 on monocytes has been shown to promote 
tumor extravasation (65). Although the type of selectin binding 
to PSGL-1 was not determined, this study further emphasizes the 
important role of selectins/selectin ligands interaction in tumor 
extravasation. P-selectin was found to be important in a metastatic 
model of melanoma and breast cancer (66). In this study, B16F1 
melanoma cells were able to metastasize in the lungs and liver of 
NK-depleted/deficient mice in a P-selectin-dependent manner. 
Intriguingly, while metastases in the lungs were dependent on 
P-selectin expression on platelets and endothelial cells, hepatic 
metastases relied only on endothelial P-selectin. From these and 
other studies, it is clear that selectins and their ligands participate 
in the extravasation of cancer cells and they also contribute, 
together with other factors, to the site-specific colonization of 
metastatic cells.
Cancer cells exhibit a metabolic shift from oxidative to 
anaerobic glycolysis, this is known as the Warburg effect, which 
corresponds to increased gene expression of sugar transporters 
and glycolytic enzymes in cancer cells and is part of the adapta-
tion of cancer cells to a hypoxic tumor microenvironment. These 
changes have been recently linked to induction of genes related 
to the expression of SLex in cancer (67). This includes ST3Gal1, 
FUT7, and uridine 5` diphosphate (UDP)-Gal transporter-1 
(UGT1), which are induced when colon cancer cells are grown 
under hypoxic conditions; interestingly, this is believed to be 
mediated by hypoxia inducible factor (HIF) (68). This leads to 
higher expression of SLex and SLea on cancer cells and is likely 
to at least partially explain the increased SLex- determinant 
expression seen in some cancers, which may be accompanied by 
a concomitant increase in E-selectin binding activity. We have 
made a similar observation in MM. When grown in culture under 
hypoxic conditions (1% O2), we have seen marked upregulation of 
ST3Gal6 transcripts along with a significant increase in E-selectin 
ligand expression (69). This process refers to the “neosynthesis” 
hypothesis related to the mechanism of enhanced expression of 
carbohydrate determinants of selectin ligands in cancers (70, 71). 
This was further examined in a study looking at the association 
between SLex and SLea expression on colon cancer cells and 
epithelial–mesenchymal transition (EMT). Induction of EMT 
was shown to increase SLex and SLea expression and enhance 
E-selectin binding. In this study, transcript levels of ST3Gal1/3/4 
and FUT3 were significantly elevated and found to be regulated 
by c-Myc. This study outlines the role of SLex and SLea expres-
sion in mediating selectin binding during EMT (72). It is thus 
possible that hypoxia and other drivers of EMT may lead to the 
mobilization of selectin ligand-bearing cells that are then capable 
of homing to distant sites where selectins are expressed.
Selectins and Tumor emboli Formation
The first association between cancer and thrombosis, and sub-
sequent microemboli formations, came from Trousseau in 1895, 
and since then, this association was further established by a large 
body of clinical evidence (73). Indeed, cancer patients often expe-
rience malignancy-associated thrombosis, which is the second 
commonest cause of cancer mortality (74). In cancer patients and 
in particular in metastatic cancer patients, the risk on thrombosis 
is associated with platelet hyperactivity (75). Cancer cells induce 
activation of platelets by different types of mechanisms; however, 
the common outcome of this activation is an increase in meta-
static spread of cancer cells (73, 76). The link between platelets 
and cancer metastases seems to be a common feature of different 
types of cancers. Moreover, platelets contribute to the metastatic 
process in many ways including enhancing tumor cell adhesion in 
the vasculature, a process where P-selectin seems to have a promi-
nent role (74, 76). Indeed, mice deficient of P-selectin had fewer 
metastases in the lungs than WT mice when injected with colon 
cancer cells (77). In the same study, it was also shown that cancer 
cells in the lung vasculature were surrounded by mouse platelets, 
an event that was greatly reduced in P-selectin−/− mice. Similarly, 
lung metastases were significantly reduced in P-selectin−/− mice 
in a syngeneic model of metastatic melanoma (78). However, 
when P-selectin was selectively deleted in platelets, melanoma 
metastasis were attenuated but not at the same extent as the KO 
mice, uncovering an essential role of endothelial P-selectin in 
lung metastasis. Subsequent studies highlighted that the absence 
of platelets not only attenuate melanoma metastasis in the lungs 
but also increase liver metastases, suggesting that platelets may 
specifically direct metastases in the lungs (66). Organ-specific 
vasculature anatomy, as well as hemodynamic, may explain in 
part the different requirement of platelets as they may assist tumor 
cell attachment in the lungs where the blood flow is naturally fast 
but are dispensable in the liver, where P-selectin expressed on 
endothelial cells is sufficient to capture tumor cells due to inher-
ently slow blood stream. Formation of tumor emboli or tumor 
aggregates may also directly regulate the expression levels of 
selectin ligands on tumor cells. Cells from the metastatic breast 
cancer line MDA-MB-231 do not roll on E-selectin in vitro (79). 
However, when cultured in 3D spheroids, these cells upregulate 
E-selectin ligands and exhibit robust rolling on E-selectin in vitro. 
Induction of E-selectin ligands on spheroids may depend on the 
secretion of pro-inflammatory cytokines, such as interleukin 6 
(IL6) and TNFα.
Selectin and the establishment of a 
Metastatic Niche
The predisposition of certain organs to support metastases of 
specific cancer is long recognized and represents the basis of the 
“seed and soil” hypothesis proposed by Steven Paget more than 
100 years ago (80). The generation of a permissive microenviron-
ment or a premetastatic niche to enable circulating cancer cells to 
colonize distant organs is crucial for an efficient establishment of 
metastases (80, 81). Several factors contribute to the formation of 
a premetastatic niche, such as primary tumor-derived secreting 
factors, exosomes, bone marrow-derived cells, and stromal cells. 
Selectins and their ligands may also contribute to shape the meta-
static niche. In a syngeneic mouse model of lung metastases, it has 
been shown that vascular endothelial growth factor (VEGF) and 
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other tumor-derived secreting factors promote focal adhesion 
kinase- (FAK)-dependent expression of E-selectin in the lung 
endothelium, thereby facilitating cancer cell homing in the lungs 
(56). Since selectins are one of the main mediators of leukocytes 
trafficking, it is conceivable that selectins contribute to leuko-
cyte recruitment at metastatic and premetastatic sites. P- and 
L-selectin-mediated interactions between tumor cells, platelets, 
and leukocytes have been shown to induce endothelial activation 
with concomitant induction of C–C Chemokine Ligand 5 (CCL5) 
expression in vitro and in vivo (82). Moreover, CCL5 expression 
could be blocked by an anti-P-selectin blocking antibody dem-
onstrating the importance of selectins in this process. Monocyte 
homing to metastatic sites was dependent on the expression of 
CLL5 from the activated endothelium, and remarkably, inhibi-
tion of monocyte recruitment greatly decreased metastases by 
reducing cancer cell survival. Subsequently, it was shown that 
monocyte recruitment at metastatic site was dependent on 
monocytic expression of PSGL-1, a well characterized ubiqui-
tously selectin ligand (65). In this study, the MC-38 GFP colon 
carcinoma cell line showed increased numbers of metastasis in 
the lungs of C57BL/6 mice compared to the FUT7-deficient mice. 
Metastases were rescued by injecting selectin ligands bearing leu-
kocytes, highlighting the importance of selectins/selectin ligands 
interactions in establishing a prometastatic niche.
Selectin and Cancer Cells Retention in 
the Niche
It has been demonstrated that E-selectin regulates hematopoietic 
stem cells (HSC) dormancy in the bone marrow niche (83). Indeed, 
HSC quiescence and self-renewal were enhanced in E-selectin−/− 
mice. Although to our knowledge, there is no evidence for such 
a role of selectins in solid tumors, retention of leukemic cells in 
their niche might be mediated in part by selectins. An example 
is represented by AML where E-selectin plays a role in retention 
and protection of the leukemic stem cells (LSC) in the bone mar-
row vascular niche (84). Indeed, LCS from an AML mouse model, 
where E-selectin was knocked out, showed greater sensitivity 
toward cytarabine compared to WT AML mice. Moreover, treat-
ment with GMI-1271, a small molecule glycomimetic, rationally 
designed based on the bioactive conformation of SLea/x and a 
potent and specific antagonist of E-selectin, caused mobilization 
of the LCS into the blood, suggesting that E-selectin contributes 
to the retention of LSC in the bone marrow vasculature niche. 
Within the bone marrow niche, E-selectin might protect AML 
cells by regulating key pathways, such as Wnt [Wingless-type 
mouse mammary tumor virus (MMTV) integration site family 
member] and sonic Hedgehog (52). E-selectin was shown to 
regulate cell cycle in LSCs of a murine retroviral transduction/
transplantation model of CML, suggesting that E-selectin may 
also be an important component of the bone marrow vascular 
niche in CML (85). In MM, PSGL-1/P-selectin interactions seem 
to be important not only for homing of malignant cells to the 
bone marrow but also in mediating the interactions between 
the malignant cells and the bone marrow niche, where PSGL-1 
regulates myeloma proliferation and resistance to therapy (35).
TARGeTiNG THe SeLeCTiNS AND THeiR 
LiGANDS
Inhibition of selectin–selectin ligand interactions could impact 
different aspects of the tumor from metastatic spread to reshaping 
the metastatic niche. The consequence of this strategy depends 
certainly on the type of cancer and the stage at diagnosis. Inhibition 
of selectin/selectin ligand interactions can be achieved by differ-
ent strategies, including inhibition of key enzymes responsible 
for generating the selectin ligands, such as STs, or blockage of 
selectin/selectin ligands interaction (Figure 3); in the latter case, 
the use of a variety of compounds can be employed spanning 
from small molecules, glycomimetics, heparin derivatives, and 
blocking antibodies.
ST inhibition
Due to the broad scope of biological processes regulated by sialic 
acid-containing glycoconjugates in both health and disease, 
many studies have aimed to develop ST inhibitors (86). While 
several of these have successfully develop potent inhibitors with 
partial selectivity against individual family members in vitro, the 
large majority of the developed compounds are not cell perme-
able, since they incorporate CMP or a derivative thereof giving 
the compounds negative charge and not enabling them to cross 
the cell membrane, let alone into the Golgi apparatus where 
their targets are located. A breakthrough in a general approach 
to developing glycosyltransferase inhibitors came when Vocadlo 
and colleagues introduced a Trojan Horse approach that involves 
the use of the cells’ own metabolic machinery to convert an 
unnatural monosaccharide into its corresponding nucleotide 
diphosphate donor substrate (87). Paulson and colleagues subse-
quently applied this approach to the development of the first cell 
permeable ST inhibitor described as 3Fax-Neu5Ac (88). Delivered 
to cells in its peracetylated form enables it to readily diffuse 
across the cell membrane, be deacetylated by cellular esterases 
and subsequently be formed into CMP-3Fax-Neu5Ac (Figure 4), 
which acts as a very poor substrate for the STs by virtue of the 
electron withdrawing effects of the fluorine substituent (89). As 
a consequence, CMP-3Fax-Neu5Ac builds up to high levels inside 
the cells and impairs the actions of all mammalian STs examined 
to date, both in vitro (88) and in vivo (90).
The therapeutic potential of 3Fax-Neu5Ac in reversing the 
hypersialylated state of cancer cells was realized by Adema and 
colleagues, where they demonstrated that treating skin melanoma 
with 3Fax-Neu5Ac prior to injecting cells into the mice greatly 
impaired tumor growth in vivo (91). These results nicely dem-
onstrated the potential of ST inhibition as a cancer therapeutic. 
Nevertheless, due to critical roles played by sialylation in healthy 
tissues, the non-selective nature of this inhibitor is a concern. 
In particular, an important role for sialylation was confirmed 
within the kidney in a study where 3Fax-Neu5Ac was systemically 
administered to mice (90). At certain doses, 3Fax-Neu5Ac caused 
irreversible kidney damage, resulting in loss of protein in within 
the urine, significant loss of weight, and the eventual death of 
the animals. A similar phenotype has also been observed in mice 
deficient in sialic acid biosynthesis (92). It is noteworthy that 
FiGURe 3 | The glycans determinants required for selectins binding are generated within the Golgi apparatus. STs, such as ST3GAL6, are responsible 
for the covalent linkage of sialic acid (⧫) to the underline sugar backbone. Once on the cell surface, selectin ligands interact with selectins mediating cell rolling on 
the vasculature endothelium. Interactions of tumor cells with platelets or the endothelium (represented in the figure) can be blocked at the level of the Golgi 
apparatus by inhibiting STs or by directly interfering with the binding to selectins using blocker antibodies (Ab) or small molecules, such as GMI-1271, among others.
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out of the numerous ST-deficient mice established to date, none 
have developed such a phenotype. Based on these observations, 
it is likely that multiple STs work together to form the negatively 
charged glomerular filtration system on podocytes within the 
kidney. Hence, selectively inhibiting an individual ST in vivo may 
be feasible without the severe secondary consequences to the host 
observed with the global ST inhibitor.
A more complete structural knowledge of the ST family may 
enable selective ST inhibitors to be developed. Without these in 
hand, however, Adema and colleagues have developed an innova-
tive approach to selectively deliver 3Fax-Neu5Ac to cells in vivo 
(22). Working with poly lactic acid (PLGA) nanoparticles to 
encapsulate 3Fax-Neu5Ac, the compound was successfully deliv-
ered to melanoma cells by virtue of an antibody displayed on the 
surface of the nanoparticles that is specific for a tumor antigen. 
Targeting 3Fax-Neu5Ac to the cancer cells in this way allowed for 
delivery of the compound to cells within mice, preventing metas-
tasis of the melanoma cells to the lung. This approach appears to 
have broad applicability for different forms of cancer, so long as a 
specific tumor antigen is known. While work in this area is still in 
its infancy, modulating ST activity with small molecule inhibitors 
is an exciting avenue with broad therapeutic potential.
Small Molecules, Blocking Antibodies, 
Glycomimetics, and Heparin Derivatives
Inhibition of P-selectin has been shown to reduce metastasis 
in  vivo in different types of tumor. In MM, PSGL-1 has been 
shown to regulate the interaction between the malignant cells 
and their microenvironment, including macrophages (35, 93). 
Moreover, PSGL-1/P-selectin interactions mediate homing of the 
myeloma cells to the bone marrow and resistance to chemotherapy 
in the context of the bone marrow niche in  vivo. Importantly, 
inhibition of PSGL-1/P-selectin interactions by the glycomimetic 
compound GMI-1070, or by humanized blocker antibodies to 
P-selectin or PSGL-1, was able to suppress homing of myeloma 
cells to the bone marrow and restore sensitivity to bortezomib 
(35, 50). Recently, holothurian glycosaminoglycan (hGAG), a 
marine compound similar to heparin sodium, has been shown 
to decrease melanoma lung metastasis in mice possible through 
the inhibition of P-selectin although other mechanisms may 
account for this effect (94). Metastases are attenuated by heparin 
and low-molecular fraction heparins whose mechanism(s) of 
action, among others, is the suppression of platelets–tumor cells 
and endothelial–tumor cells interactions following P-selectin 
inhibition (95–97). Similar mechanism(s) is shared by other 
glycan mimetics or molecules, such as sulfated hexasaccharides 
and ascidian dermatan sulfates (98, 99).
Although MM universally express ligands for P-selectin, we 
have recently shown that rolling on E-selectin is restricted to 
a minority of myeloma cells expressing functional E-selectin 
ligands (51, 69). Moreover, when xenotransplanted into a 
SCID mouse model, the E-selectin ligands expressing myeloma 
cells gave rise to a remarkably aggressive disease characterized 
by resistance to bortezomib (51). Notably, the glycomimetic 
E-selectin inhibitor GMI-1271 improved survival and restored 
FiGURe 4 | Mechanism of action of the CMP-3Fax-Neu5Ac inhibitor (see text for details).
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the anti-myeloma activity of bortezomib. GMI-1271 was also 
able to reduce leukemia burden in primary AML blasts engrafted 
non-obese diabetic (NOD) SCID IL2 receptor γ(c) null (Rγc−/−) 
mice when combined with chemotherapy (52). GMI-1271 in 
combination with standard chemotherapy showed promising 
results in reducing metastatic lesions in xenograft mouse models 
of pancreatic and breast cancer (100, 101). In the latter, it was 
also shown that GMI-1271 targets MCF7 breast cancer stem cells 
(CD44+CD24−) homing to the bone marrow, pointing out a role 
of E-selectin in bone marrow dissemination of cancer stem cells in 
breast cancer (102). A first in human experience with GMI-1271 
demonstrated favorable safety together with no mobilization of 
human stem cells (103). Targeting E-selectin may also be benefi-
cial in alleviating the side effects of chemotherapy and, therefore, 
improve patient survival and quality of life, especially in elderly 
and vulnerable patients. In this respect, inhibition of E-selectin 
by GMI-1271 was shown to alleviate mucositis, resulting from 
the recruitment of inflammatory macrophages to the damaged 
intestine after chemotherapy. Indeed, a marked upregulation 
of E-selectin was detected in the intestine following chemo or 
radiotherapy, which is critical to the recruitment of inflammatory 
cells to the mucosa (104).
Based on these results and the promising preclinical findings 
in AML, a clinical trial to determine the safety, pharmacokinetics, 
and efficacy of GMI-1271 in combination with chemotherapy in 
AML is currently going on (NCT02306291). Moreover, based on 
the emerging data implicating E-selectin and its ligands in MM, 
a phase I trial evaluating GMI-1271, as an adjunct to bortezomib-
based therapy, is planned. Molecules similar to GMI-1271 have 
also been developed, in particular GMI-1359, which exhibits 
dual specificity toward E-selectin and CXCR4. In combination 
with standard chemotherapy, this molecule showed the ability 
to reduce metastases in xenograft mouse models of pancreatic 
and prostate cancers and improved survival in a xenograft mouse 
model of AML (105–107).
exploiting Selectin/Selectin Ligand 
interactions
Targeting selectins may also represent an attractive strategy to 
deliver chemotherapeutic drugs to sites of metastases. Melanoma 
lung metastases were decreased by an E-selectin-targeted 
 polymer–drug conjugates. In this study, an E-selectin binding 
peptide was conjugated with N-(2-hydroxylpropyl) methacryla-
mide and equipped with doxorubicin or a proapoptotic peptide 
that can be released at mild pH conditions (108). The copolymer 
effectively decreased melanoma lungs metastases and significantly 
improved mice survival. As melanoma cancer cells induce the 
expression of E-selectin in the lung and liver, the copolymers were 
accumulation primarily in these tissues. A drug-free copolymer 
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was also able to prevent lung metastases, suggesting decreased 
cancer cells extravasation due to inhibition of E-selectin/selectin 
ligands interactions. Similarly, low-molecular-weight, heparin-
coated, doxorubicin-loaded liposomes were shown to inhibit 
melanoma metastases to the lungs by inhibiting tumor cells 
platelets formations (109).
Leukocytes have been functionalized by selectin-coated 
liposomes to deliver proapoptotic molecules, such as tumor 
necrosis factor related apoptosis inducing ligand (TRAIL), to 
tumor cells. E-selectin-coated liposomes containing TRAIL were 
used to “equip” circulation leukocytes with TRAIL by taking 
advantage of the interactions between E-selectin and its ligands 
expressed on the surface of leukocytes (110, 111). The “equipped” 
leukocytes were able to efficiently clear circulating colon cancer 
and prostate cancer cells in a xenograft mouse model.
FUTURe PeRSPeCTiveS
In conclusion, there is mounting evidence supporting a role 
for selectins and their ligands in cancer patients, promoting 
metastatic behavior and disease progression. The emergence of 
new therapeutic strategies will hopefully lead to an improvement 
in outcome of patients with aberrant selectin ligand expression.
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